Breaking Finance News

A statement released earlier today by RBC Capital about Karyopharm Therapeutics (NASDAQ:KPTI) bumps the target price to $14.00

Karyopharm Therapeutics (NASDAQ:KPTI) had its stock price target increased to $14.00 by RBC Capital in an issued report announced Friday September 15, 2017. The upped price target suggests a possible upside of 0.32% based on the company's most recent stock price close.

Previously on 7/06/2017, Zacks Investment Research reported on Karyopharm Therapeutics (NASDAQ:KPTI) raised the target price from $0.00 to $11.00. At the time, this indicated a possible upside of 0.14%.

Just yesterday Karyopharm Therapeutics (NASDAQ:KPTI) traded 3.97% higher at $10.57. KPTI’s 50-day average is $9.22 and its two hundred day average is $9.87. The last stock price close is up 11.34% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 106,214 shares of KPTI traded hands, down from an average trading volume of 172,938

See Chart Below

Karyopharm Therapeutics (NASDAQ:KPTI)

With a market cap of $0, Karyopharm Therapeutics has 52 week low of $6.27 and a 52 week high of $14.63 .

A total of 9 equity analysts have released a research note on Karyopharm Therapeutics. Three analysts rating the stock a strong buy, 3 firms rating the stock a buy, 1 broker rating the stock a hold, 1 broker rating the stock a underperform, and finally 0 brokers rating the stock a sell with a consensus price target of $16.56.

General Company Details For Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. The Company's lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. It is also engaged in the clinical development of selinexor in various solid tumor indications. Oral selinexor is being evaluated in multiple later-phase clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. Its lead drug candidate, oral selinexor (KPT-330), as well as verdinexor (KPT-335), KPT-8602 and KPT-9274 are in clinical development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.